: Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rally
MarketWatch
MARCH 24, 2023
IOVA on Friday said it had completed its rolling biologics license application submission to the U.S. Interim Chief Executive Frederick Vogt said in a statement that completing the submission “is a critical step forward in our journey to deliver the first individualized, one-time cell therapy for a solid tumor.”
Let's personalize your content